

ICMJE DISCLOSURE FORM

Date: 29/Jan/2021

Your Name: Tomohiro Nakayama

Manuscript Title: Gastroparesis as a significant gastrointestinal adverse event during intensive chemotherapy for solid cancer: a case report.

Manuscript number (if known): TCR-21-2776

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	_X_ None	
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	_X_ None	
3	Royalties or licenses	_X_ None	
4	Consulting fees	_X_ None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<input checked="" type="checkbox"/> None	
6	Payment for expert testimony	<input checked="" type="checkbox"/> None	
7	Support for attending meetings and/or travel	<input checked="" type="checkbox"/> None	
8	Patents planned, issued or pending	<input checked="" type="checkbox"/> None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input checked="" type="checkbox"/> None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input checked="" type="checkbox"/> None	
11	Stock or stock options	<input checked="" type="checkbox"/> None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input checked="" type="checkbox"/> None	
13	Other financial or non-financial interests	<input checked="" type="checkbox"/> None	

Please place an "X" next to the following statement to indicate your agreement:

I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: 29/Jan/2022

Your Name: Koji Haratani

Manuscript Title: Gastroparesis as a significant gastrointestinal adverse event during intensive chemotherapy for solid cancer: a case report.

Manuscript number (if known): TCR-21-2776

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	<u>_X_</u> None	
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	AstraZeneca K.K.	
		MSD K.K.	
3	Royalties or licenses	<u>_X_</u> None	

4	Consulting fees	<input checked="" type="checkbox"/> None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	AstraZeneca K.K.	
		AS ONE Corporation	
		Bristol-Myers Squibb Co. Ltd.	
		MSD K.K.	
		Ono Pharmaceutical Co. Ltd.	
6	Payment for expert testimony	<input checked="" type="checkbox"/> None	
7	Support for attending meetings and/or travel	<input checked="" type="checkbox"/> None	
8	Patents planned, issued or pending	<input checked="" type="checkbox"/> None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input checked="" type="checkbox"/> None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input checked="" type="checkbox"/> None	
11	Stock or stock options	<input checked="" type="checkbox"/> None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input checked="" type="checkbox"/> None	
13	Other financial or non-financial interests	<input checked="" type="checkbox"/> None	

Please place an "X" next to the following statement to indicate your agreement:

I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: 29/Jan/2021

Your Name: Takashi Kurosaki

Manuscript Title: Gastroparesis as a significant gastrointestinal adverse event during intensive chemotherapy for solid cancer: a case report.

Manuscript number (if known): TCR-21-2776

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	<input checked="" type="checkbox"/> None	
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	<input checked="" type="checkbox"/> None	
3	Royalties or licenses	<input checked="" type="checkbox"/> None	

4	Consulting fees	<input type="checkbox"/> None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<input type="checkbox"/> None	
6	Payment for expert testimony	<input type="checkbox"/> None	
7	Support for attending meetings and/or travel	<input type="checkbox"/> None	
8	Patents planned, issued or pending	<input type="checkbox"/> None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input type="checkbox"/> None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input type="checkbox"/> None	
11	Stock or stock options	<input type="checkbox"/> None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input type="checkbox"/> None	
13	Other financial or non-financial interests	<input type="checkbox"/> None	

Please place an "X" next to the following statement to indicate your agreement:

I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: 29/Jan/2021

Your Name: Kaoru Tanaka

Manuscript Title: Gastroparesis as a significant gastrointestinal adverse event during intensive chemotherapy for solid cancer: a case report.

Manuscript number (if known): TCR-21-2776

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	<input checked="" type="checkbox"/> None	
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	<input checked="" type="checkbox"/> None	
3	Royalties or licenses	<input checked="" type="checkbox"/> None	
4	Consulting fees	<input checked="" type="checkbox"/> None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	Eisai Co. Ltd AstraZeneca K.K. Merck Biopharma Co. Ltd. Bristol-Myers Squibb Co. Ltd. Ono Pharmaceutical Co. Ltd. MSD K.K. Kyowa Kirin Co. Ltd.	
6	Payment for expert testimony	<input checked="" type="checkbox"/> None	
7	Support for attending meetings and/or travel	<input checked="" type="checkbox"/> None	
8	Patents planned, issued or pending	<input checked="" type="checkbox"/> None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input checked="" type="checkbox"/> None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input checked="" type="checkbox"/> None	
11	Stock or stock options	<input checked="" type="checkbox"/> None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input checked="" type="checkbox"/> None	
13	Other financial or non-financial interests	<input checked="" type="checkbox"/> None	

Please place an "X" next to the following statement to indicate your agreement:

I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: 29/Jan/2021

Your Name: Kazuhiko Nakagawa

Manuscript Title: Gastroparesis as a significant gastrointestinal adverse event during intensive chemotherapy for solid cancer: a case report.

Manuscript number (if known): TCR-21-2776

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	<u> X </u> None	
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	AbbVie Inc.	
		Astellas Pharma Inc.	
		AstraZeneca K.K.	
		A2 Healthcare Corp.	
		Bayer Yakuhin Ltd.	
		Bristol Myers Squibb Co. Ltd.	
		Chugai Pharmaceutical Co. Ltd.	
		CMIC Shift Zero K.K.	
		Covance Japan Inc.	
		Daiichi Sankyo Co. Ltd.	
		Eisai Co. Ltd.	

		Eli Lilly Japan K.K.	
		EPS Corporation.	
		EPS International Co. Ltd.	
		EPS International Co. Ltd.	
		ICON Japan K.K.	
		IQVIA Services JAPAN K.K.	
		Japan Clinical Research Operations	
		Kissei Pharmaceutical Co. Ltd.	
		Kyowa Kirin Co. Ltd.	
		MSD K.K.	
		Medical Research Support	
		Merck Serono Co. Ltd.	
		Merck Biopharma Co. Ltd.	
		Mochida Pharmaceutical Co. Ltd.	
		Nippon Boehringer Ingelheim Co. Ltd.	
		Novartis Pharma K.K.	
		Ono Pharmaceutical Co. Ltd.	
		Otsuka Pharmaceutical Co. Ltd.	
		PAREXEL International Corp.	
		Pfizer Japan Inc.	
		Pfizer R&D Japan G.K.	
		PPD-SNBL K.K.	
		PRA HEALTHSCIENCES	
		Sanofi K.K.	
		SymBio Pharmaceuticals Limited.	
		Syneos Health	
		System Corporation	
		Taiho Pharmaceutical Co. Ltd.	
		Takeda Pharmaceutical Co. Ltd.	
3	Royalties or licenses	_X_ None	
4	Consulting fees	Eli Lilly Japan K.K.	
		Kyorin Pharmaceutical Co. Ltd.	
		Ono Pharmaceutical Co. Ltd.	
		Pfizer Japan Inc.	
		Takeda Pharmaceutical Co. Ltd.	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	AbbVie Inc.	
		Amgen Inc.	
		Astellas Pharma Inc.	
		AstraZeneca K.K.	
		Bayer Yakuhin Ltd.	
		Bristol Myers Squibb Co. Ltd.	
		Care Net Inc.	
		Chugai Pharmaceutical Co. Ltd.	
		Eli Lilly Japan K.K.	
		Daiichi Sankyo Co. Ltd.	
		Hisamitsu Pharmaceutical Co. Inc.	

		Kyorin Pharmaceutical Co. Ltd.	
		Kyowa Kirin Co. Ltd.	
		Nichi-Iko Pharmaceutical Co. Ltd.	
		Medical Mobile Communications Co. Ltd	
		Merck Biopharma Co. Ltd.	
		Merck Serono Co. Ltd.	
		MSD K.K.	
		Nippon Boehringer Ingelheim Co. Ltd.	
		Nippon Kayaku Co. Ltd.	
		Novartis Pharma K.K.	
		Pfizer Japan Inc.	
		Ono Pharmaceutical Co. Ltd.	
		Roche Diagnostics K.K.	
		Taiho Pharmaceutical Co. Ltd.	
		Takeda Pharmaceutical Co. Ltd.	
		Thermo Fisher Scientific K.K.	
		3H Clinical Trial Inc.	
6	Payment for expert testimony	<input type="checkbox"/> None	
7	Support for attending meetings and/or travel	<input type="checkbox"/> None	
8	Patents planned, issued or pending	Daiichi-Sankyo Co. Ltd.	WO2015048804A2, WO2018123999A1, and WO2018159582A1
		Ono Pharmaceutical Co. Ltd.	
		Sysmex Co. Ltd.	Japanese Patent 2018-59834
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input type="checkbox"/> None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input type="checkbox"/> None	
11	Stock or stock options	<input type="checkbox"/> None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input type="checkbox"/> None	
13	Other financial or non-financial interests	<input type="checkbox"/> None	

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.